EyePoint Pharmaceuticals

Press Releases

pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Oct 18, 2017
Conference Call Scheduled for 8:30 a.m. ET on Tuesday, November 7th
pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
Oct 10, 2017
Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds
pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
Sep 26, 2017
WATERTOWN, Mass. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has signed an agreement with a major global pharmaceutical company to develop two glaucoma drugs with pSivida's proprietary
pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 22, 2017
WATERTOWN, Mass. , Sept. 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2017
pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
Sep 11, 2017
Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis Conference Call and Webcast Today, September 11th , at 4:30 p.m. ET WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained
pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 11, 2017
WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual
pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th
Sep 05, 2017
WATERTOWN, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, will report results for its fourth quarter and fiscal year ended June 30, 2017 on Monday,
pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
Aug 01, 2017
WATERTOWN, Mass. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases, today announced that Nancy Lurker , President and Chief Executive Officer, will present at the
Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
Jul 18, 2017
WATERTOWN, Mass. , July 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that three abstracts supporting the Company's Durasert™ three-year treatment for posterior segment uveitis
pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida's Revenue Generation
Jul 10, 2017
WATERTOWN, Mass. , July 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences, Inc.
pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
Jun 28, 2017
WATERTOWN, Mass. , June 28, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Kristine Peterson , a seasoned healthcare executive has been elected to the Company's Board of
pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union
Jun 22, 2017
WATERTOWN, Mass. , June 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market
pSivida's Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
Jun 13, 2017
Highly Significant Difference Observed Between Durasert and Control Group  in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 p.m.ET WATERTOWN, Mass. , June 13, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
May 08, 2017
Positive Data Presented at the Association for Research in Vision and Ophthalmology Annual Meeting pSivida Anticipates Reporting Top Line Results from the Second Pivotal Phase 3 Clinical Trial in June 2017 WATERTOWN, Mass. , May 08, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.
pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
May 04, 2017
 EU and US Calendar 2017 Registration Filing Milestones for Durasert™ for Posterior Segment Uveitis Remain on Schedule Conference Call and Webcast Today, May 4th , at 4:30 p.m. ET WATERTOWN, Mass. , May 04, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
Apr 19, 2017
WATERTOWN, Mass. , April 19, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the third quarter of fiscal year 2017 will be released
Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Mar 15, 2017
WATERTOWN, Mass. , March 15, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that an abstract supporting the Company's Durasert three-year treatment for posterior segment uveitis has
pSivida to Present at the 2017 BIO CEO & Investor Conference
Feb 10, 2017
WATERTOWN, Mass. , Feb. 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the company and its progress
pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results
Feb 07, 2017
EU and U.S. 2017 Registration Filing Milestones for Durasert™ for Posterior Segment Uveitis Remain on Track Conference Call and Webcast Today, February 7 , at 4:30 p.m. ET WATERTOWN, Mass. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
Jan 25, 2017
WATERTOWN, Mass. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the second quarter of fiscal year 2017 will be released
Displaying 41 - 60 of 326
EyePoint Pharmaceuticals